BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6339028)

  • 1. The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
    Oken MM; Costello WG; Johnson GJ; Lenhard RE; Ezdinli EZ; Orlow E; Barnes JM; Berard CW; Glick JH
    Cancer; 1983 May; 51(9):1581-6. PubMed ID: 6339028
    [No Abstract]   [Full Text] [Related]  

  • 2. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
    Ezdinli EZ; Anderson JR; Melvin F; Glick JH; Davis TE; O'Connell MJ
    J Clin Oncol; 1985 Jun; 3(6):769-75. PubMed ID: 3839262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic chemotherapy in lymphoma.
    Mukherji B; Oettgen HF; Yagoda A; Krakoff IH
    Cancer; 1971 Oct; 28(4):886-93. PubMed ID: 4939250
    [No Abstract]   [Full Text] [Related]  

  • 5. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of combined chemotherapy of lymphosarcoma with cyclophosphamide, vincristine and prednisolone].
    Abdyldaev RA; Kruglova GV
    Vopr Onkol; 1983; 29(4):83-5. PubMed ID: 6687966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the indolent non-Hodgkin's lymphomas.
    Portlock CS
    Semin Oncol; 1980 Sep; 7(3):292-301. PubMed ID: 6158100
    [No Abstract]   [Full Text] [Related]  

  • 11. [Non-Hodgkin's lymphoma in children. Study of 30 patients at the Caracas University Hospital].
    Acquatella G; Urdaneta N; Rosas Uribe A; García Guevara R
    Sangre (Barc); 1985; 30(3):253-83. PubMed ID: 3839940
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
    Weick JK; Jones SE; Haut A; Fisher R; Dixon D
    Cancer Treat Rep; 1981; 65(7-8):611-4. PubMed ID: 6166373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
    Lenhard RE; Ezdinli EZ; Costello W; Bennett JM; Horton J; Amorisi EL; Stolbach L; Wolter J
    Cancer; 1978 Jul; 42(1):41-52. PubMed ID: 352507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy for advanced diffuse non-Hodgkin's lymphomas in relapse following local radiotherapy].
    Sampi K; Honda T; Hattori M
    Rinsho Hoshasen; 1983 Jun; 28(6):673-7. PubMed ID: 6688641
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
    Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
    Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.
    Ezdinli EZ; Harrington DP; Kucuk O; Silverstein MW; Anderson J; O'Connell MJ
    Cancer; 1987 Jul; 60(2):156-60. PubMed ID: 3297278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
    Somoza N; Pavlovsky S; Suárez A; Morgenfeld M; Besuschio SC; Bezares R; Quiroga Micheo E; Lein JM; De María H
    Medicina (B Aires); 1981; 41 Suppl():35-43. PubMed ID: 7345350
    [No Abstract]   [Full Text] [Related]  

  • 19. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Durant JR; Loeb V; Dorfman R; Chan YK
    Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Present status and future problems in non-Hodgkin's lymphoma. III. On the chemotherapy of non-Hodgkin's lymphoma (author's transl)].
    Sakano T
    Rinsho Ketsueki; 1981 Feb; 22(2):159-77. PubMed ID: 7031290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.